V CompBrief BY VELARION

Chief Financial Officer, Secretary, and Treasurer · Monopar Therapeutics (MNPR)

Quan Vu

FY2025 is the first fiscal year CompBrief holds for Quan Vu as a named executive officer of Monopar Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$2,101,314

3rd of 3 named executive officers at Monopar Therapeutics by FY2025 total.

3 named officers on file for Monopar Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Monopar Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Monopar Therapeutics’s whole pay program stands against its peers

  • Monopar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MNPR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Quan Vu’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Quan Vu and every company like it: Velarion Intel, free for 3 days, no card →

Quan Vu compensation by year

Monopar Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Monopar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$305,000
Bonus$100,000
Stock awards$746,186
Option awards$795,061
Non-equity incentive$137,250
Pension and deferred compensation$0
All other$17,816
Total$2,101,314

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Monopar Therapeutics DEF 14A filed April 30, 2026, accession 0001437749-26-014183, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Monopar Therapeutics filed document, accession 0001437749-26-014183. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU9,826$641,638—
Option20,312—$30.93
Option7,135—$75.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Monopar Therapeutics's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Monopar Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Chandler RobinsonChief Executive Officer and Director$10,637,821
Andrew CittadineChief Operating Officer$4,706,431
Quan Vu · this pageChief Financial Officer, Secretary, and Treasurer$2,101,314

Quan Vu's compensation dossier, Monopar Therapeutics

You have read Quan Vu's totals and holdings. The dossier adds each equity grant Monopar Therapeutics disclosed for Quan Vu and Monopar Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Monopar Therapeutics compensation record

free company brief
Monopar Therapeutics (MNPR) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within Monopar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Monopar Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Monopar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order MNPR

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Quan Vu's compensation dossier